UniQure slides after FDA says inadequate clinical data for Huntington's therapy
03/11/2025 12:51
** U.S.-listed shares of Dutch biotech UniQure NV UQ1.F, QURE.O fall nearly 67.5% to about $22 in premarket trading ** FDA says clinical data for co's Huntington's disease therapy is not adequate ** As of last close, shares up about 283.3% YTD (Reporting by Parth Chandna) ((Parth.Chandna@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal